XML 67 R50.htm IDEA: XBRL DOCUMENT
v3.24.0.1

The Company and Basis of Presentation (Details) $ / shares in Units, $ in Thousands |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 106 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 11, 2023 USD ($) $ / shares shares | Jun. 26, 2023 USD ($) shares | Jun. 22, 2023 $ / shares shares | Dec. 31, 2023 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) shares | Apr. 30, 2023 | Jun. 30, 2023 | Dec. 31, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) $ / shares | Dec. 31, 2021 USD ($) | Dec. 31, 2023 USD ($) $ / shares | Dec. 08, 2023
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Employee workforce, termination percentage |  |  |  |  |  | 83.00% | 83.00% |  |  |  |  |
Proceeds from issuance of private placement |  |  |  |  |  |  |  | $ 84,555 | $ 0 | $ 0 |  |
Proceeds from raising capital |  |  |  |  |  |  |  |  |  |  | $ 896,200 |
Accumulated deficit |  |  |  | $ 764,414 |  |  |  | 764,414 | $ 425,624 |  | 764,414 |
Cash, cash equivalents, and marketable securities |  |  |  | $ 339,300 |  |  |  | $ 339,300 |  |  | $ 339,300 |
Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Fixed exchange ratio |  |  | 0.5494488 |  |  |  |  |  |  |  |  |
Asset acquisition, stockholder payment period |  |  | 3 years |  |  |  |  |  |  |  |  |
Spyre 2023 Equity Incentive Plan | Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Number of outstanding and unexercised stock options to purchase (in shares) | shares |  |  | 2,734 |  |  |  |  |  |  |  |  |
Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, par value (in dollars per share) | $ / shares |  |  |  | $ 0.0001 |  |  |  | $ 0.0001 | $ 0.0001 |  | $ 0.0001 |
Conversion basis |  |  | 40 |  |  |  |  |  |  |  |  |
Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock | Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares transferred as equity interest in asset acquisition (in shares) | shares |  |  | 364,887 |  |  |  |  |  |  |  |  |
Preferred stock, par value (in dollars per share) | $ / shares |  |  | $ 0.0001 |  |  |  |  |  |  |  |  |
Conversion basis |  |  | 40 |  |  |  |  |  |  |  |  |
Series B Non-Voting Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Conversion basis | 40 |  |  |  |  |  |  |  |  |  |  | 40
Series B non-voting convertible preferred stock, par value (in dollars per share) | $ / shares | $ 0.0001 |  |  | $ 0.0001 |  |  |  | $ 0.0001 | $ 0.0001 |  | $ 0.0001 |
Private Placement |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Sale of stock (in shares) | shares |  | 721,452 |  |  | 721,452 |  |  |  |  |  |  |
Proceeds from issuance of private placement | $ 180,000 | $ 210,000 |  |  |  |  |  | $ 180,000 |  |  |  |
Offering costs | $ 10,900 | 12,700 |  | $ 10,900 | $ 12,700 |  |  |  |  |  |  |
Private Placement | Series A Non Voting Convertible Preferred StockSeries A Non Voting Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placement |  | $ 210,000 |  |  |  |  |  |  |  |  |  |
Private Placement | Series B Non-Voting Convertible Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Sale of stock (in shares) | shares | 150,000 |  |  | 150,000 |  |  |  |  |  |  |  |
Proceeds from issuance of private placement | $ 90,000 |  |  |  |  |  |  |  |  |  |  |
Common Stock | Spyre Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Shares transferred as equity interest in asset acquisition (in shares) | shares |  |  | 517,809 |  |  |  |  |  |  |  |  |
Common Stock | Private Placement |  |  |  |  |  |  |  |  |  |  |  |
Company and Basis of Presentation [Line Items] |  |  |  |  |  |  |  |  |  |  |  |
Sale of stock (in shares) | shares | 6,000,000 |  |  | 6,000,000 |  |  |  |  |  |  |  |

X
- Definition Asset acquisition consideration transferred equity interest issued and issuable, shares. + References No definition available. + Details
Name: | syre_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuableShares
Namespace Prefix: | syre_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Stockholder Payment Period + References No definition available. + Details
Name: | syre_AssetAcquisitionStockholderPaymentPeriod
Namespace Prefix: | syre_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Company and basis of presentation. + References No definition available. + Details
Name: | syre_CompanyAndBasisOfPresentationLineItems
Namespace Prefix: | syre_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fixed exchange ratio. + References No definition available. + Details
Name: | syre_FixedExchangeRatio
Namespace Prefix: | syre_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Outstanding and unexercised stock options. + References No definition available. + Details
Name: | syre_OutstandingAndUnexercisedStockOptions
Namespace Prefix: | syre_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds From Raising Capital + References No definition available. + Details
Name: | syre_ProceedsFromRaisingCapital
Namespace Prefix: | syre_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details
Name: | us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion for each share of preferred stock to be converted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of accumulated undistributed earnings (deficit). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (27) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_TemporaryEquityParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=syre_SpyreTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=syre_Spyre2023EquityIncentivePlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=syre_SeriesANonVotingConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=syre_SeriesBNonVotingConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |